Search

Your search keyword '"PLASMA SCD36"' showing total 2 results
Start Over Descriptor "PLASMA SCD36"
2 results on '"PLASMA SCD36"'

1. CD36 gene polymorphism and plasma sCD36 as the risk factor in higher cholesterolemia.

Author

Rać, M.E., Safranow, K., Garanty-Bogacka, B., Dziedziejko, V., Kurzawski, G., Goschorska, M., Kuligowska, A., Pauli, N., and Chlubek, D.

Subjects
*SYNDROMES, *METABOLIC syndrome, *METABOLIC disorders, *FIBRINOGEN polymorphisms, *HYPERCHOLESTEREMIA
Abstract

Introduction The receptor CD36 has been reported to play an important role in atherogenicity. The aim of this study was to gain insight into the relationship between CD36 gene polymorphisms or the plasma concentration of sCD36 and clinical or biochemical parameters in children. Patients and methods The study groups comprised Caucasian children with and without hypercholesterolemia. The alterations in the CD36 gene were detected by DHPLC and the plasma concentrations of sCD36 were measured by ELISA. Results The data presented suggest that the IVS4-10A allele of CD36 (rs3211892) is associated with a lower risk of hypercholesterolemia. We observed a negative correlation of the sCD36 concentration with uric acid and insulin concentrations, the HOMA-IR ratio, weight, waist and hip circumference, systolic blood pressure, body mass index, waist–hip ratio and mean arterial pressure ratio, but a positive correlation with HDL cholesterol and ApoA1 concentrations. Female gender was a significant independent predictor of a higher plasma sCD36 concentration. Conclusions The data presented suggest a possible protective effect of a higher sCD36 concentration in relation to metabolic syndrome components. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

2. Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease

Author

Angels Betriu, Maria Rosa Sarrias, Marcelino Bermudez-Lopez, José Maria Valdivielso, Elvira Fernández, Josep Franch-Nadal, Berta Soldevila, Per-Henrik Groop, Didac Mauricio, Maria Barranco-Altirriba, Núria Alonso, Esmeralda Castelblanco, Universitat Politècnica de Catalunya. Departament d'Enginyeria de Sistemes, Automàtica i Informàtica Industrial, HUS Abdominal Center, Research Programs Unit, Department of Medicine, Per Henrik Groop / Principal Investigator, Clinicum, Nefrologian yksikkö, and CAMM - Research Program for Clinical and Molecular Metabolism

Subjects
Male, Aging, Cardiovascular system--Diseases, Informàtica::Automàtica i control [Àrees temàtiques de la UPC], PROGRESSION, 030204 cardiovascular system & hematology, GLOMERULAR-FILTRATION-RATE, 0302 clinical medicine, Risk Factors, Sistema cardiovascular--Malalties, Cause of Death, Chronic kidney disease, AIM, Myocardial infarction, MACROPHAGES, RISK, Receptors, Scavenger, 0303 health sciences, APOPTOSIS INHIBITOR, Biochemical markers, Middle Aged, 3. Good health, Cardiovascular Diseases, Marcadors bioquímics, Cardiology, Female, SOLUBLE CD36, Research Paper, medicine.medical_specialty, Ciències de la salut::Medicina [Àrees temàtiques de la UPC], Renal function, PLASMA SCD36, CD5L, Cardiovascular events, 03 medical and health sciences, cardiovascular events, Kidneys--Diseases, Internal medicine, Diabetes mellitus, medicine, Mortalitat, Humans, Renal Insufficiency, Chronic, Mortality, 030304 developmental biology, Aged, business.industry, Unstable angina, Cell Biology, medicine.disease, sCD36, mortality, Blood pressure, ATHEROSCLEROSIS, Gene Expression Regulation, Heart failure, 3121 General medicine, internal medicine and other clinical medicine, Ronyons--Malalties, 1182 Biochemistry, cell and molecular biology, business, Apoptosis Regulatory Proteins, Dyslipidemia, chronic kidney disease, Biomarkers, Kidney disease
Abstract

This study assessed the association of CD5L and soluble CD36 (sCD36) with the risk of a cardiovascular event (CVE), including CV death and all-cause mortality in CKD. We evaluated the association of CD5L and sCD36 with a predefined composite CV endpoint (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular accident, congestive heart failure, arrhythmia, peripheral arterial disease [PAD] or amputation by PAD, aortic aneurysm, or death from CV causes) and all-cause mortality using Cox proportional hazards regression, adjusted for CV risk factors. The analysis included 1,516 participants free from pre-existing CV disease followed up for 4 years. The median age was 62 years, 38.8% were female, and 26.8% had diabetes. There were 98 (6.5%) CVEs and 72 (4.8%) deaths, of which 26 (36.1%) were of CV origin. Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0-1.36), and all-cause mortality (1.22, 1.01-1.48) after adjusting for age, sex, diabetes, systolic blood pressure, dyslipidemia, waist circumference, smoking, and CKD stage. sCD36 showed no association with adverse CV outcomes or mortality. Our study showed for the first time that higher concentrations of CD5L are associated with future CVE and all-cause mortality in individuals with CKD. This research was supported by grants from the European Foundation for the Study of Diabetes (2014-EFSD-00914) Düsseldorf, Germany; the European Regional Development Fund; and the Carlos III National Institute of Health (PI14/1772) Madrid, Spain. CIBER for Diabetes and Associated Metabolic Diseases (CIBERDEM) and CIBER on Liver and Digestive Diseases (CIBEREHD) are an initiative of ISCIII, Madrid, Spain. The NEFRONA study is funded by a research grant from AbbVie, Lake County, Illinois.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results